Sign In
Buy SLP
$16.17
-0.600 (-3.58%)
At Close: Jun 03, 2026
Simulations Plus, Inc. (SLP) Analyst/Investor Day Transcript
08:16pm, Wednesday, 21'st Jan 2026
Simulations Plus, Inc. (SLP) Analyst/Investor Day Transcript
ROSEN, A LONGSTANDING LAW FIRM, Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP
05:32pm, Wednesday, 21'st Jan 2026
New York, New York--(Newsfile Corp. - January 21, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Sim
Simulations Plus Highlights Platform Innovation and Strategic Direction at 2026 Investor Day
04:05pm, Wednesday, 21'st Jan 2026
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development
NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Simulations Plus,
Johnson Fistel Investigates Simulations Plus for Potential Securities Law Violations
09:31am, Tuesday, 20'th Jan 2026
SAN DIEGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP announces that it is investigating potential claims on behalf of investors of Simulations Plus, Inc. (NASDAQ: SLP) regarding possible
New York, New York--(Newsfile Corp. - January 18, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Simu
Simulations Plus Q1 Earnings Call Highlights
02:02am, Saturday, 10'th Jan 2026
Simulations Plus (NASDAQ: SLP) reported fiscal first-quarter 2026 results that management said came in line with internal expectations, as strength in services offset a year-over-year decline in softw
SLP Stock Crashes on Q1 Earnings Miss, Software Headwinds Hurt Sales
08:25am, Friday, 09'th Jan 2026
Simulations Plus Q1 fiscal 2026 EPS miss as software revenue fall 17%, but services momentum and strong bookings support confidence for the rest of fiscal 2026.
Simulations Plus, Inc. (SLP) Q1 2026 Earnings Call Transcript
07:54pm, Thursday, 08'th Jan 2026
Simulations Plus, Inc. (SLP) Q1 2026 Earnings Call Transcript
Market Today: GM's $7B EV Reset, Defense Stocks Pop, Hyundai's Robot Push
05:35pm, Thursday, 08'th Jan 2026
Stock News Silicon Valley split on CA wealth tax: Alphabet's cofounders moved assets out of California while Nvidia's Jensen Huang said he's âperfectly fineâ
Simulations Plus Reports First Quarter Fiscal 2026 Financial Results
04:05pm, Thursday, 08'th Jan 2026
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development
Simulations Plus, Inc. (NASDAQ:SLP) Receives Consensus Recommendation of “Hold” from Analysts
01:12am, Tuesday, 23'rd Dec 2025
Simulations Plus, Inc. (NASDAQ: SLP - Get Free Report) has been assigned an average recommendation of "Hold" from the eleven research firms that are covering the stock, MarketBeat.com reports. One equ
Simulations Plus (SLP) Upgraded to Strong Buy: Here's What You Should Know
01:01pm, Thursday, 18'th Dec 2025
Simulations Plus (SLP) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Simulations Plus to Host Virtual Investor Day Highlighting Strategy for the Next Era of Model-Informed Drug Development
07:50am, Thursday, 18'th Dec 2025
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development
Simulations Plus Announces First Quarter Fiscal Year 2026 Earnings and Conference Call Date
07:50am, Wednesday, 17'th Dec 2025
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a global leader in model-informed and AI-accelerated drug development that adva
